Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Oculis Holding AG (OCS : NSDQ)

• Company Description    Oculis Holding AG is a biopharmaceutical company which develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. Its product candidate includes OCS-01, OCS-02 and OCS-05. Oculis Holding AG is based in Zug, Switzerland. Number of Employees: 60

• Price / Volume Information    Yesterday's Closing Price: $12.16 Daily Weekly Monthly 20 Day Moving Average: 155,589 shares Shares Outstanding: 57.98 (millions) Market Capitalization: $705.09 (millions) Beta: 0.52 52 Week High: $34.48 52 Week Low: $10.52 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -4.63% -3.95% 12 Week 6.20% 3.96% Year To Date -39.11% -45.68%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL BAHNHOFSTRASSE 20 - ZUG,V8 6300 CHE ph: 41-41-711-3960 fax: - ir@oculis.com http://www.oculis.com

• General Corporate Information    Officers Riad Sherif - Chief Executive Officer Anthony Rosenberg - Chairman Sylvia Cheung - Chief Financial Officer Christina Ackermann - Director Lionel Carnot - Director Peer Information Oculis Holding AG (CORR.) Oculis Holding AG (RSPI) Oculis Holding AG (CGXP) Oculis Holding AG (BGEN) Oculis Holding AG (GTBP) Oculis Holding AG (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: H5870P102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/09/26 Share - Related Items Shares Outstanding: 57.98 Most Recent Split Date: (:1) Beta: 0.52 Market Capitalization: $705.09 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.48 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.01 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/09/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.54 Price/Cash Flow: - Price / Sales: 483.27 EPS Growth vs. Year Ago Period: 66.10% vs. Previous Quarter: 68.25% Sales Growth vs. Year Ago Period: 24.05% vs. Previous Quarter: 46.82% ROE 06/30/26 - -42.61 03/31/26 - -56.78 12/31/25 - -62.12 ROA 06/30/26 - -35.23 03/31/26 - -45.62 12/31/25 - -49.74 Current Ratio 06/30/26 - 8.35 03/31/26 - 5.18 12/31/25 - 5.96 Quick Ratio 06/30/26 - 8.35 03/31/26 - 5.18 12/31/25 - 5.96 Operating Margin 06/30/26 - -6,777.18 03/31/26 - -8,460.67 12/31/25 - -8,173.41 Net Margin 06/30/26 - -6,777.18 03/31/26 - -8,460.67 12/31/25 - -8,173.41 Pre-Tax Margin 06/30/26 - -6,956.07 03/31/26 - -8,653.00 12/31/25 - -8,269.94 Book Value 06/30/26 - 4.79 03/31/26 - 4.33 12/31/25 - 4.08 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - 0.01 03/31/26 - 0.01 12/31/25 - 0.01 Debt-to-Capital 06/30/26 - 0.81 03/31/26 - 0.92 12/31/25 - 0.92

Powered by Zacks Investment Research ©